tiprankstipranks
Pharming price target lowered to $30 from $31 at Oppenheimer
PremiumThe FlyPharming price target lowered to $30 from $31 at Oppenheimer
2M ago
Is PHAR a Buy, Before Earnings?
Premium
Pre-Earnings
Is PHAR a Buy, Before Earnings?
2M ago
Pharming Group Delays Leniolisib EU Approval
Premium
Company Announcements
Pharming Group Delays Leniolisib EU Approval
7M ago
Pharming Group Lauded for Rare Disease Treatment
PremiumCompany AnnouncementsPharming Group Lauded for Rare Disease Treatment
8M ago
Pharming Completes Trial Enrollment for Pediatric Drug
Premium
Company Announcements
Pharming Completes Trial Enrollment for Pediatric Drug
9M ago
Joenja’s Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
Premium
Company Announcements
Joenja’s Journey: Navigating the Market Risks and Regulatory Challenges Post-Approval for Pharming Group Nv
9M ago
Pharming management to meet with Oppenheimer
PremiumThe FlyPharming management to meet with Oppenheimer
1y ago
Pharming management to meet with Oppenheimer
Premium
The Fly
Pharming management to meet with Oppenheimer
1y ago
Pharming Group price target raised to EUR 1.90 from EUR 1.80 at RBC Capital
Premium
The Fly
Pharming Group price target raised to EUR 1.90 from EUR 1.80 at RBC Capital
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100